In one paragraphArticle in Brain : a journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Grace MinogueMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Antonia ZouridakisMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0002-6404-3558 Caroline NelsonMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Allegra KawlesMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0003-3153-5350 Rachel KeszyckiMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Alyssa MacomberMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0009-0008-0355-9332 Sandra WeintraubMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0003-2605-5205 Nathan GillMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Qinwen MaoMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0001-7876-2046 Pouya JamshidiMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Rudolph CastellaniMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
M-Marsel MesulamMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.ORCID 0000-0001-5731-851X Changiz GeulaMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Tamar GefenMesulam Institute for Cognitive Neurology & Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Funding
Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI VASSAR, ROBERT J · 1996 to 2020
$28.9MResearch Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROBERT J VASSAR · 2021 to 2026
$26.3MASYMMETRIC NEURODEGENERATION AND LANGUAGE IN PRIMARY PROGRESSIVE APHASIAR01AG077444 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MAREK-MARSEL M MESULAM, EMILY J ROGALSKI · 2022 to 2026
$10.4MPREDOCTORAL AND POSTDOCTORAL TRAINING PROGRAM IN AGING AND DEMENTIAT32AG020506 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROBERT J VASSAR, SANDRA WEINTRAUB · 2002 to 2026
$9.9MTRAINING PROGRAM IN THE NEUROSCIENCE OF HUMAN COGNITIONT32NS047987 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Rodrigo M Braga, Christina Maria Zelano · 2006 to 2026
$5.6MConcordance of TDP-43 Inclusions with Cortical Atrophy and Clinical PhenotypeR01NS085770 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GEULA, CHANGIZ · 2014 to 2024
$5.0MClinical, Neuroanatomic, and Pathologic Signatures of FTLD-tau in Dementia Phenotypes - Diversity Supplement (Antwan Howard)R01AG062566 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI GEFEN, TAMAR D · 2020 to 2024
$2.1MDeterminants of Neurodegenerative Decline in Primary Progressive AphasiaR01NS075075 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 2012 to 2016
$1.7MPathologic Substrates of Neuropsychiatric Symptoms in Aphasic DementiaF31AG076318 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI KESZYCKI, RACHEL M · 2022 to 2024
$122kNIA NIH HHS F31 AG076318NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG072977NIA NIH HHS R01 AG062566NIA NIH HHS R01 AG077444NIA NIH HHS T32 AG020506NINDS NIH HHS R01 NS075075NINDS NIH HHS R01 NS085770NINDS NIH HHS T32 NS047987
6 · The paper itselfAbstract
Corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP) comprise the majority of 4-repeat (4R) tauopathy cases of frontotemporal lobar degeneration (FTLD-tau). Both pathologic entities can underlie clinical syndromes such as primary progressive aphasia (PPA), characterized by an isolated, progressive impairment of language and left-predominant atrophy, and behavioral variant frontotemporal dementia (bvFTD), marked by progressive personality changes and more symmetric frontotemporal atrophy. In this study, we investigated the neocortical and hippocampal distributions of neuronal and glial tau inclusions in CBD and PSP to establish clinicopathologic concordance between tau pathology and the aphasic versus behavioral phenotype. Twenty-eight right-handed cases with autopsy-confirmed CBD (n=14) or PSP (n=14) were identified from the Northwestern University Alzheimer's Disease Research Center brain bank (PPA, n=16; bvFTD, n=12). Paraffin-embedded sections were immunohistochemically stained with AT8 to visualize tau pathology, and modified unbiased stereological analysis was performed in up to eight regions, including the middle frontal gyrus (MFG), superior temporal gyrus (STG), inferior parietal lobule (IPL), anterior temporal lobe (ATL), dentate gyrus (DG), CA1 of the hippocampus, and primary visual cortex (V1). In PPA, pathology was significantly left-lateralized, with the ATL showing the highest overall tau burden, while bvFTD cases showed more symmetric or rightward distributions with peak pathology in the MFG. Across both syndromes, CBD cases exhibited greater neuronal tau pathology, and PSP cases exhibited greater glial tau pathology, with this double-dissociation reaching significance across neocortex. Hippocampal regions, particularly CA1, showed higher neuronal tau burden than neocortical regions regardless of clinical phenotype, and DG tau burden was significantly greater in CBD than PSP (p<0.01). Inclusion-to-neuron analyses revealed disproportionately higher tau burden in the DG compared to neocortex, especially in CBD (p<0.001). These findings reveal syndrome- and pathology- specific patterns of selective cellular and regional vulnerability in 4R-tauopathies and support clinicopathologic concordance in PPA and bvFTD.
Indexed as
and progressive supranuclear palsybehavioral variant frontotemporal dementiacorticobasal degenerationfrontotemporal lobar degenerationprimary progressive aphasia
Identifiers
PMID42219867
PMCPMC13387371
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390